View in EDS

Phase 1 Study of IMC-002, a Next-Generation Anti-CD47 Antibody, in Advanced Solid Tumors.

Saved in:

Bibliographic Details
Title:	Phase 1 Study of IMC-002, a Next-Generation Anti-CD47 Antibody, in Advanced Solid Tumors.
Authors:	Ahn JS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Hong JY; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Park JO; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Lee SY; ImmuneOncia Therapeutics Inc., Seoul, Korea., Kim S; ImmuneOncia Therapeutics Inc., Seoul, Korea., Yun HY; College of Pharmacy, Chungnam National University, Daejeon, Korea., Ock CY; Lunit Inc., Seoul, Korea., Hwang W; Lunit Inc., Seoul, Korea., Kim SH; ImmuneOncia Therapeutics Inc., Seoul, Korea., Kim HT; ImmuneOncia Therapeutics Inc., Seoul, Korea., Lim HY; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Source:	Cancer research and treatment [Cancer Res Treat] 2025 Nov 04. Date of Electronic Publication: 2025 Nov 04.
Publication Type:	Journal Article
Journal Info:	Publisher: Korean Cancer Association Country of Publication: Korea (South) NLM ID: 101155137 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2005-9256 (Electronic) Linking ISSN: 15982998 NLM ISO Abbreviation: Cancer Res Treat Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	2005-9256
DOI:	10.4143/crt.2025.820